Azacitadine

Phase 3Small molecule

AbbVie

Azacitadine is one of 44 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Leukemia, Myeloid, AcuteRecruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Leukemia, Myeloid, AcutePhase 1

Recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 2

Retin-a

VValeant Pharmaceuticals

Phase 3

2 3

Caspofungin Acetate

Merck & Co.

Phase 3

1 4

AG-120

Institut de Recherches Internationales Servier

Phase 3

4 5

Low-Dose Cytarabine

Bristol-Myers Squibb

Phase 3

2 6

Azacitadine

AbbVie

Phase 3

1 7

Leukine

Sanofi

Preclinical

7 8

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

8 9

Antibiotic

Pfizer

Preclinical

1 10

Daurismo

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Chemotherapy

NCT05317403

Q4 2028

Phase 1Recruiting

Leukemia, Myeloid, Acute

NCT06651229

Clinical

Trials by Indication[1]

Newly Diagnosed1 trial

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02845297·67 enrolled

Chemotherapy1 trial

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05317403·40 enrolled

Hematological Malignancies1 trial

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02265731·38 enrolled

Acute Myeloid Leukemia1 trial

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·PPETHEMA Foundation·Phase 3·NCT02319135·289 enrolled

Leukemia, Myeloid, Acute1 trial

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06651229·155 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Azacitadine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azacitadine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azacitadine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Azacitadine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Newly Diagnosed1 trial

Chemotherapy1 trial

Hematological Malignancies1 trial

Acute Myeloid Leukemia1 trial

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News